Current status of angiogenesis inhibitors combined with radiation therapy

Cancer Treatment Reviews

Volumn 32, Issue 5, 2006, Pages 348-364

  Nieder, Carsten ^a   Wiedenmann, Nicole ^b   Andratschke, Nicolaus ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Cancer; Radiosensitizer; Radiotherapy; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CHIMERIC PROTEIN; COMBRETASTATIN A4; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; IRINOTECAN; MONOCLONAL ANTIBODY; N ACETYLCOLCHINOL PHOSPHATE; NEUTRALIZING ANTIBODY; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RIBOZYME; RITONAVIR; SORAFENIB; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; IONIZING RADIATION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLOGY; PUBLICATION; RADIATION DOSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; RADIOTHERAPY DOSAGE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745976468     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.03.006     Document Type: Review

References (104)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 46 (1986) 467-473
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
4. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
5. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
6. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
7. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
8. Teicher B.A., Sotomayor E.A., and Huang Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52 (1992) 6702-6704
9. Siemann D.W., Warrington K.H., and Horsman M.R. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 57 (2000) 5-12
10. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
11. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
12. Xu L., Tong R., Cochran D.M., and Jain R.K. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65 (2005) 5711-5719
13. Andratschke N., Nieder C., Price R.E., et al. Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 32 Suppl. 3 (2005) S67-S70
14. Andratschke N.H., Nieder C., Price R.E., et al. Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 60 (2004) 1257-1263
15. Thula T.T., Schultz G., Tran-Son-Tay R., and Batich C. Effects of EGF and bFGF on irradiated parotid glands. Ann Biomed Eng 33 (2005) 685-695
16. Kerbel R.S., Viloria-Petit A., Okada F., and Rak J. Establishing a link between oncogenes and tumor angiogenesis. J Mol Med 4 (1998) 286-295
17. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
18. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9 (2005) 777-794
19. Carmeliet P., and Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 902 (2000) 249-262
20. Fukumoto S., Morifuji M., Katakura Y., et al. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22 (2005) 31-38
21. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14 (1977) 53-65
22. Jakeman L.B., Winer J., Bennett G.L., et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89 (1992) 244-253
23. Guo D., Jia Q., Song H.Y., et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270 (1995) 6729-6733
24. Stoletov K.V., Ratcliffe K.E., Spring S.C., and Terman B.I. NCK and PAK participate in the signaling pathway by which vascular endothelial growth factor stimulates the assembly of focal adhesions. J Biol Chem 276 (2001) 22748-22755
25. di Tomaso E., Capen D., Haskell A., et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 65 (2005) 5740-5749
26. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
27. Borgström P., Hillan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56 (1996) 4032-4039
28. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
29. Prewett M., Huber J., Li Y., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59 (1999) 5209-5218
30. Bruns C.J., Liu W., Davis D.W., et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89 (2000) 488-499
31. Lee C.G., Heijn M., di Tomaso E., et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
32. Kozin S.V., Boucher Y., Hicklin D.J., et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 6 (2001) 39-44
33. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 (2002) 47-54
34. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
35. Yuan F., Chen Y., Dellian M., et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93 (1996) 14765-14770
36. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 (2000) 4152-4160
37. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60 (2000) 970-975
38. Schuuring J., Bussink J., Bernsen H., et al. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 61 (2005) 529-534
39. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
40. Heissig B., Rafii S., Akiyama H., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202 (2005) 739-750
41. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
42. Sonveaux P., Brouet A., Havaux X., et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63 (2003) 1012-1019
43. Fukumura D., Gohongi T., Kadambi A., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98 (2001) 2604-2609
44. Kashiwagi S., Izumi Y., Gohongi T., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115 (2005) 1816-1827
45. Zips D., Hessel F., Krause M., et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 61 (2005) 908-914
46. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
47. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
48. Huber P.E., Bischof M., Jenne J., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
49. Ning S., Laird D., Cherrington J.M., and Knox S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157 (2002) 45-51
50. Hess C., Vuong V., Hegyi I., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001) 2010-2016
51. Dings R.P., Williams B.W., Song C.W., et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 115 (2005) 312-319
52. Haimovitz-Friedman A., Vlodavsky I., Chaudhuri A., et al. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51 (1991) 2552-2558
53. Fuks Z., Persaud R.S., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54 (1994) 2582-2590
54. Kermani P., Leclerc G., Martel R., and Fareh J. Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys 50 (2001) 213-220
55. Brieger J., Schroeder P., Gosepath J., and Mann W.J. VEGF-subtype specific protection of SCC and HUVECs from radiation induced cell death. Int J Mol Med 15 (2005) 145-151
56. Murata R., Nishimura Y., and Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37 (1997) 1107-1113
57. Leith J.T., Papa G., Quaranto L., and Michelson S. Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br J Cancer 66 (1992) 345-348
58. Ansiaux R., Baudelet C., Jordan B.F., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 (2005) 743-750
59. Rofstad E.K., Henriksen K., Galappathi K., et al. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 63 (2003) 4055-4061
60. Murata R., Siemann D.W., Overgaard J., et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60 (2001) 155-161
61. Griffin R.J., Williams B.W., Wild R., et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62 (2002) 1702-1706
62. Kozin SV, Boucher Y, di Tomaso E, et al. Glomerulopathy in mice treated with whole-body irradiation and VEGFR2-blocking antibody. In: 49th annual meeting of the Radiation Research Society, Reno, Nevada; 2002. p. 8-65.
63. Kumar P., Benedict R., Urzua F., et al. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 85 (2005) 756-767
64. McDonnell C.O., Holden G., Sheridan M.E., et al. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res 116 (2004) 19-23
65. Willett C.G., Chung D., Sahani D., et al. Phase I study of neoadjuvant bevacizumab, 5-fluorouracil and radiation therapy followed by surgery for patients with primary rectal cancer [Abstract]. J Clin Oncol 22 (2004) 267s
66. Crane C.H., Varadhachary G., Pisters P., et al. Novel chemoradiation in localized pancreatic cancer: clinical studies. In: Brown J.M., Mehta M.P., and Nieder C. (Eds). Multimodal concepts for integration of cytotoxic drugs and radiation therapy (2006), Springer, Heidelberg 215-229
67. Szczylik C., Eisen T., Stadler W.M., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma [Abstract]. J Clin Oncol 23 (2005) 1093s
68. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
69. Sandler A.B., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599 [Abstract]. J Clin Oncol 23 (2005) 2s
70. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
71. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
72. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [Abstract]. J Clin Oncol 23 (2005) 1s
73. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92 (1995) 10457-10461
74. Lin P., Sankar S., Shan S., et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9 (1998) 49-58
75. Goldman C.K., Kendall R.L., Cabrera G., et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95 (1998) 8795-8800
76. Im S.A., Gomez-Manzano C., Fueyo J., et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59 (1999) 895-900
77. Fenton B.M., Paoni S.F., and Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res 64 (2004) 5712-5719
78. Li J., Huang S., Armstrong E.A., et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62 (2005) 1477-1485
79. Machein M.R., Risau W., and Plate K.H. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10 (1999) 1117-1128
80. Parry T.J., Cushman C., Gallegos A.M., et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 27 (1999) 2569-2577
81. Rockwell P., O'Connor W.J., King K., et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 94 (1997) 6523-6528
82. Damiano V., Melisi D., Bianco C., et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11 (2005) 5639-5644
83. Frederick B., Gustafson D., Bianco C., et al. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 33-37
84. Sun J., Wang D.A., Jain R.K., et al. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24 (2005) 4701-4709
85. Shinohara E.T., Cao C., Niermann K., et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24 (2005) 5414-5422
86. Siemann D.W., and Rojiani A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62 (2005) 846-853
87. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
88. Maggiorella L., Wen B., Frascogna V., et al. Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res 25 (2005) 4357-4362
89. Shi W., and Siemann D.W. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25 (2005) 3899-3904
90. Kal H.B., Struikmans H., Gebbink M.F., and Voest E.E. Response of rat prostate and lung tumors to ionizing radiation combined with the angiogenesis inhibitor AMCA. Strahlenther Onkol 180 (2004) 798-804
91. Teicher B.A., Holden S.A., Ara G., et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38 (1996) 169-177
92. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
93. Lu B., Geng L., Musiek A., et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys 58 (2004) 844-850
94. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61 (2001) 2413-2419
95. Lund E.L., Olsen M.W., Lipson K.E., et al. Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia 5 (2003) 11-16
96. Gong H., Pöttgen C., Stüben G., et al. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 106 (2003) 723-728
97. Salloum R.M., Jaskowiak N.T., Mauceri H.J., et al. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 60 (2000) 6958-6963
98. Lund E.L., Olsen M.W., Lipson K.E., et al. Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia 5 (2003) 11-16
99. Edwards E., Geng L., Tan J., et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62 (2002) 4671-4677
100. Geng L., Tan J., Himmelfarb E., et al. A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res 64 (2004) 4893-4899
101. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53 (2002) 164-171
102. Mauceri H.J., Hanna N.N., Beckett M.A., et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394 (1998) 287-291
103. Gorski D.H., Mauceri H.J., Salloum R.M., et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58 (1998) 5686-5689
104. Griscelli F., Li H., Cheong C., et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 97 (2000) 6698-6703